{"nctId":"NCT01200368","briefTitle":"Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants","startDateStruct":{"date":"2010-09-24","type":"ACTUAL"},"conditions":["Healthy Subjects"],"count":551,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Biological: 13-valent pneumococcal conjugate vaccine (13vPnC)","Biological: diphtheria, tetanus, and acellular pertussis vaccine (DTaP)"]},{"label":"2","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: 7-valent pneumococcal conjugate vaccine (7vPnC)","Biological: DTaP"]},{"label":"3","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: DTaP"]}],"interventions":[{"name":"13-valent pneumococcal conjugate vaccine (13vPnC)","otherNames":[]},{"name":"diphtheria, tetanus, and acellular pertussis vaccine (DTaP)","otherNames":[]},{"name":"7-valent pneumococcal conjugate vaccine (7vPnC)","otherNames":[]},{"name":"DTaP","otherNames":[]},{"name":"DTaP","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female subjects between 3 to 6 months of age at the enrollment.\n* Available for the entire study period and whose parent/legal guardian can be reached by telephone.\n* Healthy infant as determined by medical history, physical examination, and judgement of the investigator.\n\nExclusion Criteria:\n\n* Previous vaccination with licensed or investigational pneumococcal, diphtheria, tetanus, or pertussis vaccines.\n* A previous anaphylactic reaction to any vaccine or vaccine-related component.\n* Bleeding diathesis or condition associated with prolonged bleeding time that would contraindicate any type of injection.\n* History of culture-proven invasive disease caused by S pneumoniae (eg, meningitis, bacteremia, osteomyelitis, arthritis).\n* Infant who is a direct descendant (child, grandchild) of the study site personnel.","healthyVolunteers":false,"sex":"ALL","minimumAge":"3 Months","maximumAge":"6 Months","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level Greater Than or Equal to (>=) 0.35 Microgram Per Milliliter (mcg/mL) 1 Month After the Infant Series","description":"Percentage of participants achieving predefined antibody threshold \\>=0.35 mcg/mL along with the corresponding 95% confidence interval (CI) for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.9","spread":null},{"groupId":"OG001","value":"96.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.7","spread":null},{"groupId":"OG001","value":"98.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"96.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"96.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.3","spread":null},{"groupId":"OG001","value":"96.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"96.6","spread":null}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 7 Common Serotypes 1 Month After the Infant Series","description":"Antibody geometric mean concentration (GMC) for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"9.40","spread":null},{"groupId":"OG001","value":"11.54","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.50","spread":null},{"groupId":"OG001","value":"5.71","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.04","spread":null},{"groupId":"OG001","value":"6.80","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.86","spread":null},{"groupId":"OG001","value":"16.79","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.30","spread":null},{"groupId":"OG001","value":"7.26","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.37","spread":null},{"groupId":"OG001","value":"8.38","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.64","spread":null},{"groupId":"OG001","value":"4.53","spread":null}]}]}]},{"type":"PRIMARY","title":"Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Infant Series","description":"Predefined antibody levels were 0.1 International Units/mL (IU/mL) for diphtheria, 0.01 IU/mL for tetanus, 5 Enzyme-linked Immunosorbent Assay (ELISA) units/mL (EU/mL) for pertussis toxoid (PT), and 5 EU/mL for filamentous hemagglutinin (FHA).","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"96.6","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody for 6 Additional Serotypes 1 Month After the Infant Series","description":"Antibody GMC for 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% CIs were evaluated. GMs were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"8.14","spread":null},{"groupId":"OG001","value":"4.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.90","spread":null},{"groupId":"OG001","value":"4.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.64","spread":null},{"groupId":"OG001","value":"4.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.71","spread":null},{"groupId":"OG001","value":"4.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.26","spread":null},{"groupId":"OG001","value":"4.53","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.56","spread":null},{"groupId":"OG001","value":"4.53","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody Level >=0.35 mcg/mL 1 Month After the Toddler Dose","description":"Percentage of participants achieving predefined antibody threshold \\>=0.35 mcg/mL along with the corresponding 95% CI for the 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. Exact 2-sided CI based on the observed proportion of participants. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest response observed among the 7 common serotypes in the group was taken as reference.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"98.7","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"99.4","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"99.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After the Toddler Dose","description":"Antibody GMC as measured by mcg/mL for 7 common pneumococcal serotypes (serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F) and 6 additional pneumococcal serotypes specific to 13vPnC (Serotypes 1, 3, 5, 6A, 7F, and 19A) are presented. GMC (13vPnC) and corresponding 2-sided 95% confidence intervals (CI) were evaluated. Geometric means (GMs) were calculated using all participants with available data for the specified blood draw. To demonstrate non-inferiority, for 6 additional serotypes in 7vPnC + DTaP group, the lowest GMC observed among the 7 common serotypes in the group was taken as reference.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"15.34","spread":null},{"groupId":"OG001","value":"16.35","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.05","spread":null},{"groupId":"OG001","value":"13.91","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.00","spread":null},{"groupId":"OG001","value":"8.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.70","spread":null},{"groupId":"OG001","value":"20.69","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.10","spread":null},{"groupId":"OG001","value":"9.88","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.73","spread":null},{"groupId":"OG001","value":"9.55","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8.64","spread":null},{"groupId":"OG001","value":"10.00","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.96","spread":null},{"groupId":"OG001","value":"8.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.48","spread":null},{"groupId":"OG001","value":"8.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.10","spread":null},{"groupId":"OG001","value":"8.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"15.17","spread":null},{"groupId":"OG001","value":"8.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.90","spread":null},{"groupId":"OG001","value":"8.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.02","spread":null},{"groupId":"OG001","value":"8.64","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving Predefined Antibody Levels for Diphtheria Toxoid, Tetanus Toxoid, and Pertussis Antigens 1 Month After the Toddler Dose","description":"Predefined antibody level was 0.1 IU/mL for diphtheria, 0.01 IU/mL for tetanus, 5 EU/mL for PT, and 5 EU/mL for FHA.","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"100.0","spread":null},{"groupId":"OG001","value":"100.0","spread":null},{"groupId":"OG002","value":"100.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibodies 1 Month After the Infant Series","description":"GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.03","spread":null},{"groupId":"OG001","value":"1.10","spread":null},{"groupId":"OG002","value":"0.93","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.50","spread":null},{"groupId":"OG001","value":"1.37","spread":null},{"groupId":"OG002","value":"1.66","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibodies 1 Month After the Infant Series","description":"GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"66.12","spread":null},{"groupId":"OG001","value":"57.26","spread":null},{"groupId":"OG002","value":"67.64","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.30","spread":null},{"groupId":"OG001","value":"53.86","spread":null},{"groupId":"OG002","value":"67.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) for Antigen-specific Diphtheria and Tetanus Antibody 1 Month After the Toddler Dose","description":"GMC was measured in IU/mL and corresponding 2-sided 95% CI were evaluated for diphtheria and tetanus antibodies.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.65","spread":null},{"groupId":"OG001","value":"3.18","spread":null},{"groupId":"OG002","value":"2.63","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.90","spread":null},{"groupId":"OG001","value":"2.60","spread":null},{"groupId":"OG002","value":"2.89","spread":null}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Concentration (GMC) for Antigen-specific Acellular Pertussis Antibody 1 Month After the Toddler Dose","description":"GMC was measured in EU/mL and corresponding 2-sided 95% CI were evaluated for PT and FHA antibodies.","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"144.46","spread":null},{"groupId":"OG001","value":"135.65","spread":null},{"groupId":"OG002","value":"150.21","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"143.68","spread":null},{"groupId":"OG001","value":"141.19","spread":null},{"groupId":"OG002","value":"180.31","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 1 (3 to 6 Months of Age)","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \\[cm\\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"58.5","spread":null},{"groupId":"OG001","value":"55.8","spread":null},{"groupId":"OG002","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.2","spread":null},{"groupId":"OG001","value":"51.2","spread":null},{"groupId":"OG002","value":"10.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.9","spread":null},{"groupId":"OG001","value":"18.1","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"41.1","spread":null},{"groupId":"OG001","value":"35.7","spread":null},{"groupId":"OG002","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"38.1","spread":null},{"groupId":"OG001","value":"31.5","spread":null},{"groupId":"OG002","value":"4.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.3","spread":null},{"groupId":"OG001","value":"12.7","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.6","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":null},{"groupId":"OG001","value":"6.1","spread":null},{"groupId":"OG002","value":"1.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.0","spread":null},{"groupId":"OG001","value":"60.9","spread":null},{"groupId":"OG002","value":"12.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 2 (4 to 8 Months of Age)","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \\[cm\\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.7","spread":null},{"groupId":"OG001","value":"61.9","spread":null},{"groupId":"OG002","value":"36.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"56.0","spread":null},{"groupId":"OG001","value":"56.9","spread":null},{"groupId":"OG002","value":"34.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.1","spread":null},{"groupId":"OG001","value":"27.0","spread":null},{"groupId":"OG002","value":"8.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"48.1","spread":null},{"groupId":"OG001","value":"50.9","spread":null},{"groupId":"OG002","value":"24.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"44.4","spread":null},{"groupId":"OG001","value":"48.2","spread":null},{"groupId":"OG002","value":"22.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.7","spread":null},{"groupId":"OG001","value":"17.8","spread":null},{"groupId":"OG002","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.5","spread":null},{"groupId":"OG001","value":"4.5","spread":null},{"groupId":"OG002","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"71.3","spread":null},{"groupId":"OG001","value":"67.1","spread":null},{"groupId":"OG002","value":"40.2","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-Specified Local Reactions: Infant Series Dose 3 (5 to 10 Months of Age)","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \\[cm\\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53.6","spread":null},{"groupId":"OG001","value":"51.2","spread":null},{"groupId":"OG002","value":"23.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"47.3","spread":null},{"groupId":"OG001","value":"43.1","spread":null},{"groupId":"OG002","value":"21.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.1","spread":null},{"groupId":"OG001","value":"22.1","spread":null},{"groupId":"OG002","value":"2.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"43.9","spread":null},{"groupId":"OG001","value":"37.6","spread":null},{"groupId":"OG002","value":"21.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.1","spread":null},{"groupId":"OG001","value":"34.0","spread":null},{"groupId":"OG002","value":"20.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","spread":null},{"groupId":"OG001","value":"14.9","spread":null},{"groupId":"OG002","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.8","spread":null},{"groupId":"OG001","value":"7.1","spread":null},{"groupId":"OG002","value":"2.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.0","spread":null},{"groupId":"OG001","value":"55.8","spread":null},{"groupId":"OG002","value":"28.8","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-Specified Local Reactions: Toddler Dose (12 to 15 Months of Age)","description":"Local reactions were reported using an electronic diary. Tenderness was scaled as Any (tenderness present); Significant (present and interfered with limb movement). Redness and swelling were scaled as Any (redness or swelling present); Mild (0.5 centimeters \\[cm\\] to 2.0 cm); Moderate (2.5 to 7.0 cm); Severe (\\> 7.0 cm). Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"62.2","spread":null},{"groupId":"OG001","value":"57.2","spread":null},{"groupId":"OG002","value":"34.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"50.0","spread":null},{"groupId":"OG001","value":"47.7","spread":null},{"groupId":"OG002","value":"28.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"27.7","spread":null},{"groupId":"OG001","value":"27.3","spread":null},{"groupId":"OG002","value":"13.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0","spread":null},{"groupId":"OG001","value":"45.8","spread":null},{"groupId":"OG002","value":"26.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.9","spread":null},{"groupId":"OG001","value":"42.0","spread":null},{"groupId":"OG002","value":"22.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.8","spread":null},{"groupId":"OG001","value":"18.8","spread":null},{"groupId":"OG002","value":"13.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","spread":null},{"groupId":"OG001","value":"10.0","spread":null},{"groupId":"OG002","value":"5.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.7","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"68.6","spread":null},{"groupId":"OG001","value":"61.8","spread":null},{"groupId":"OG002","value":"37.1","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 1 (3 to 6 Months of Age)","description":"Systemic events (any fever \\>= 37.5 degrees Celsius \\[C\\], decreased appetite, irritability, increased sleep, decreased sleep, and hives \\[urticaria\\]) were reported using an electronic diary. Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.3","spread":null},{"groupId":"OG001","value":"33.9","spread":null},{"groupId":"OG002","value":"21.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.6","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG002","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.9","spread":null},{"groupId":"OG001","value":"9.2","spread":null},{"groupId":"OG002","value":"7.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.8","spread":null},{"groupId":"OG001","value":"16.5","spread":null},{"groupId":"OG002","value":"12.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"28.8","spread":null},{"groupId":"OG001","value":"26.7","spread":null},{"groupId":"OG002","value":"21.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.3","spread":null},{"groupId":"OG001","value":"21.3","spread":null},{"groupId":"OG002","value":"13.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"1.2","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.7","spread":null},{"groupId":"OG001","value":"2.5","spread":null},{"groupId":"OG002","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.0","spread":null},{"groupId":"OG001","value":"59.8","spread":null},{"groupId":"OG002","value":"43.0","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 2 (4 to 8 Months of Age)","description":"Systemic events (any fever \\>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \\[urticaria\\]) were reported using an electronic diary. Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"36.7","spread":null},{"groupId":"OG001","value":"36.6","spread":null},{"groupId":"OG002","value":"21.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.9","spread":null},{"groupId":"OG001","value":"3.9","spread":null},{"groupId":"OG002","value":"0.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":null},{"groupId":"OG001","value":"14.5","spread":null},{"groupId":"OG002","value":"7.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.9","spread":null},{"groupId":"OG001","value":"18.7","spread":null},{"groupId":"OG002","value":"10.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.7","spread":null},{"groupId":"OG001","value":"22.2","spread":null},{"groupId":"OG002","value":"22.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"12.1","spread":null},{"groupId":"OG002","value":"12.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.5","spread":null},{"groupId":"OG001","value":"1.3","spread":null},{"groupId":"OG002","value":"1.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":null},{"groupId":"OG001","value":"4.5","spread":null},{"groupId":"OG002","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.2","spread":null},{"groupId":"OG001","value":"57.4","spread":null},{"groupId":"OG002","value":"44.6","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-Specified Systemic Events: Infant Series Dose 3 (5 to 10 Months of Age)","description":"Systemic events (any fever \\>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \\[urticaria\\]) were reported using an electronic diary. Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"34.6","spread":null},{"groupId":"OG001","value":"30.4","spread":null},{"groupId":"OG002","value":"24.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.3","spread":null},{"groupId":"OG001","value":"2.0","spread":null},{"groupId":"OG002","value":"3.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.7","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"9.9","spread":null},{"groupId":"OG001","value":"9.7","spread":null},{"groupId":"OG002","value":"5.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","spread":null},{"groupId":"OG001","value":"14.7","spread":null},{"groupId":"OG002","value":"11.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"20.5","spread":null},{"groupId":"OG001","value":"20.4","spread":null},{"groupId":"OG002","value":"14.9","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"12.8","spread":null},{"groupId":"OG002","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":null},{"groupId":"OG001","value":"0.0","spread":null},{"groupId":"OG002","value":"1.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.0","spread":null},{"groupId":"OG001","value":"3.3","spread":null},{"groupId":"OG002","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"57.7","spread":null},{"groupId":"OG001","value":"50.0","spread":null},{"groupId":"OG002","value":"40.9","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Percentage of Participants Reporting Pre-Specified Systemic Events: Toddler Dose (12 to 15 Months of Age)","description":"Systemic events (any fever \\>= 37.5 degrees C, decreased appetite, irritability, increased sleep, decreased sleep, and hives \\[urticaria\\]) were reported using an electronic diary. Participants may be represented in more than 1 category.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"49.0","spread":null},{"groupId":"OG001","value":"49.3","spread":null},{"groupId":"OG002","value":"31.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"8.8","spread":null},{"groupId":"OG002","value":"3.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.4","spread":null},{"groupId":"OG001","value":"2.2","spread":null},{"groupId":"OG002","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.6","spread":null},{"groupId":"OG001","value":"19.9","spread":null},{"groupId":"OG002","value":"9.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.2","spread":null},{"groupId":"OG001","value":"21.3","spread":null},{"groupId":"OG002","value":"16.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"18.6","spread":null},{"groupId":"OG001","value":"17.6","spread":null},{"groupId":"OG002","value":"16.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":null},{"groupId":"OG001","value":"9.5","spread":null},{"groupId":"OG002","value":"11.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.6","spread":null},{"groupId":"OG001","value":"2.2","spread":null},{"groupId":"OG002","value":"2.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"7.1","spread":null},{"groupId":"OG001","value":"9.4","spread":null},{"groupId":"OG002","value":"4.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.8","spread":null},{"groupId":"OG001","value":"63.8","spread":null},{"groupId":"OG002","value":"50.3","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":5,"n":183},"commonTop":["Redness (Any)","Redness (Mild)","Fever >=37.5, =<39 degrees C","Upper respiratory tract infection","Swelling (Any)"]}}}